Technology | Stents Bare Metal | December 14, 2017

FDA Approves New Indication for NuMed CP Stent System

Covered stent may now be used to patch blood vessel tears during transcatheter valve replacements

FDA Approves New Indication for NuMed CP Stent System

December 14, 2017 — The U.S. Food and Drug Administration (FDA) announced clearance for NuMed’s Cheatham Platinum (CP) Stent System, which includes the Covered CP Stent and the Covered Mounted CP Stent. The Covered CP Stent is a metal framework covered with cloth to patch a blood vessel tear in patients born with heart defects. The device was approved previously to reopen a blocked or narrowed aorta.

The stents are compressed and placed using a balloon-in-balloon (BiB) catheter. The catheter is inserted through the skin in the upper leg (groin) and pushed through the blood vessels until it reaches the target location. The stent is then expanded with the balloon. Once the stent is in place, the balloon catheter is removed from the body.

Patients born with heart defects often receive a pulmonary valve conduit (a tube with a valve inside), also known as a right ventricular outflow tract (RVOT) conduit. The RVOT conduit is used to correct the defects. Over time, the conduit may become narrowed or leaky and will need to be replaced. If a patient who has previously had a conduit implanted needs a new pulmonic valve, one option for replacement is the use of a transcatheter heart valve (THV). As part of the procedure to replace the pulmonic valve a BiB catheter is used to widen the area where the new valve will be located. Sometimes, this process causes the RVOT conduit to rupture or tear. The Covered CP Stent is used to cover the tear in the conduit before implanting a THV.

If the Covered CP stent is able to successfully close the tear in the RVOT conduit, the surgeon may be able to continue implanting the new THV. If this approach is possible, the new valve can be implanted without open-heart surgery. In a clinical study of 50 patients, about 9 out of 10 had successful closure of the conduit tear with use of the Covered CP Stent followed by successful implantation of a pulmonic valve.

  • The Covered CP Stents should not be used in patients who:
  • Are too small to allow safe delivery of the stent without injury to a systemic vein or to the right side of the heart;
  • Exhibit clinical or biological signs of infection;
  • Have active infection in the heart (endocarditis); and/or
  • Are pregnant.

For more information: www.numedinc.com

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init